Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

NEXT STORY
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
PREV STORY
Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

author_avatar
NASDAQ Market News

BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

author_avatar
NASDAQ Market News

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT NOVEMBER 1, 2019

author_avatar
NASDAQ Market News